Mostrar el registro sencillo del ítem
dc.contributor.author
Lizaraso Soto, Frank
dc.contributor.author
Gutiérrez Abejón, Eduardo
dc.contributor.author
Bustamante Munguira, Juan
dc.contributor.author
Martín García, Débora
dc.contributor.author
Chimeno, María Montserrat
dc.contributor.author
Nava Rebollo, Álvaro
dc.contributor.author
Maurtua Briseño Meiggs, Álvaro
dc.contributor.author
Fernández, Darío
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Bustamante Munguira, Elena
dc.contributor.author
de Paz, Félix Jesús
dc.contributor.author
Grande Villoria, Jesús
dc.contributor.author
Ochoa Sangrador, Carlos
dc.contributor.author
Pascual, Manuel
dc.contributor.author
Álvarez, F. Javier
dc.contributor.author
Herrera Gómez, Francisco
dc.date.available
2022-03-03T11:55:21Z
dc.date.issued
2021-08
dc.identifier.citation
Lizaraso Soto, Frank; Gutiérrez Abejón, Eduardo; Bustamante Munguira, Juan; Martín García, Débora; Chimeno, María Montserrat; et al.; Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials; Frontiers Media; Frontiers in Medicine; 8; 8-2021; 1-11
dc.identifier.issn
2296-858X
dc.identifier.uri
http://hdl.handle.net/11336/152820
dc.description.abstract
This manuscript presents findings from the first dichotomous data pooling analysis on clinical trials (CT) regarding the effectiveness of binding potassium. The results emanated from pairwise and network meta-analyses aiming evaluation of response to commercial potassium-binding polymers, that is, to achieve and maintain normal serum potassium (n = 1,722), and the association between this response and an optimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) needing individuals affected by heart failure (HF) or resistant hypertension, who may be consuming other hyperkalemia-inducing drugs (HKID) (e.g., b-blockers, heparin, etc.), and frequently are affected by chronic kidney disease (CKD) (n = 1,044): According to the surface under the cumulative ranking area (SUCRA), sodium zirconium cyclosilicate (SZC) (SUCRA >0.78), patiromer (SUCRA >0.58) and sodium polystyrene sulfonate (SPS) (SUCRA <0.39) were different concerning their capacity to achieve normokalemia (serumpotassiumlevel (sK+) 3.5–5.0mEq/L) or acceptable kalemia (sK+ ≤5.1mEq/L) in individuals with hyperkalemia (sK+ >5.1 mEq/L), and, when normokalemia is achieved, patiromer 16.8–25.2 g/day (SUCRA = 0.94) and patiromer 8.4–16.8 g/day (SUCRA = 0.41) can allow to increase the dose of spironolactone up to 50 mg/day in subjects affected by heart failure (HF) or with resistant hypertension needing treatment with other RAASi. The potential of zirconium cyclosilicate should be explored further, as no data exists to assess properly its capacity to optimize dosing of RAASi, contrarily as it occurs with patiromer. More research is also necessary to discern between benefits of binding potassium among all type of hyperkalemic patients, for example, patients with DM who may need treatment for proteinuria, patients with early hypertension, etc.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
HYPERKALEMIA
dc.subject
META-ANALYSIS (AS TOPIC)
dc.subject
MINERALOCORTICOID RECEPTOR ANTAGONISTS
dc.subject
NANOMEDICINE
dc.subject
POTASSIUM-BINDING POLYMERS
dc.subject.classification
Sistemas Cardíaco y Cardiovascular
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-01-06T14:51:58Z
dc.journal.volume
8
dc.journal.pagination
1-11
dc.journal.pais
Suiza
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Lausana
dc.description.fil
Fil: Lizaraso Soto, Frank. Universidad de Valladolid; España
dc.description.fil
Fil: Gutiérrez Abejón, Eduardo. Universidad de Valladolid; España
dc.description.fil
Fil: Bustamante Munguira, Juan. Universidad de Valladolid; España
dc.description.fil
Fil: Martín García, Débora. Universidad de Valladolid; España
dc.description.fil
Fil: Chimeno, María Montserrat. Hospital Virgen de la Concha; España
dc.description.fil
Fil: Nava Rebollo, Álvaro. Hospital Virgen de la Concha; España
dc.description.fil
Fil: Maurtua Briseño Meiggs, Álvaro. Woodland Medical Practicenhs; Reino Unido
dc.description.fil
Fil: Fernández, Darío. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina. Universidad Nacional de Cuyo; Argentina. Universidad de Burgos. Departamento de Didácticas Específicas; España
dc.description.fil
Fil: Bustamante Munguira, Elena. Universidad de Valladolid; España
dc.description.fil
Fil: de Paz, Félix Jesús. Universidad de Valladolid; España
dc.description.fil
Fil: Grande Villoria, Jesús. Universidad de Valladolid; España. Universite de Lausanne; Suiza
dc.description.fil
Fil: Ochoa Sangrador, Carlos. Sanidad de Castilla y León; España
dc.description.fil
Fil: Pascual, Manuel. Universite de Lausanne; Suiza
dc.description.fil
Fil: Álvarez, F. Javier. Universidad de Valladolid; España
dc.description.fil
Fil: Herrera Gómez, Francisco. Universite de Lausanne; Suiza. Universidad de Valladolid; España
dc.journal.title
Frontiers in Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fmed.2021.686729
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fmed.2021.686729/full
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416895/
Archivos asociados